PMC4900101_01
41-year-old man with scrotal AVM. Doppler ultrasound demonstrates abnormally increased flow through the right scrotal vasculature.
gr1.jpg
PMC4900101_01_gr1.jpg
fig1
A scrotal ultrasound demonstrated significant right-sided scrotal wall edema and hypervascularity, with marked arterial and venous flow on color Doppler (Fig. 1).
41-year-old man with scrotal AVM. Pelvic angiography on initial presentation demonstrates a right-sided scrotal AVM and prominent scrotal vasculature (arrow).
gr2.jpg
PMC4900101_01_gr2.jpg
fig2
In the interventional radiology suite, catheter-based angiography confirmed a large right-sided scrotal AVM (Fig. 2).
41-year-old man with scrotal AVM. During the initial treatment, flow through the AVM is occluded following the placement of six microcoils (arrows).
gr3.jpg
PMC4900101_01_gr3.jpg
fig3
Angiography showed marked reduction in flow through the AVM (Fig. 3).
41-year-old man with scrotal AVM. Increased flow through the AVM and right scrotal vasculature following the second bleeding episode.
gr4.jpg
PMC4900101_01_gr4.jpg
fig4
Angiography demonstrated brisk flow through the same AVM (Fig. 4).
41-year-old man with scrotal AVM. Following the second bleeding episode, treatment with more microcoils, Embospheres , and gelfoam (arrows) results in decreased but persistent flow through the right scrotal vasculature.
gr5.jpg
PMC4900101_01_gr5.jpg
fig5
Angiography exhibited decreased but persistent flow through the AVM (Fig. 5).
41-year-old man with scrotal AVM. One month following the second embolization procedure, there is markedly increased flow through the AVM and right scrotal vasculature (arrow).
gr6.jpg
PMC4900101_01_gr6.jpg
fig6
Angiography revealed a dominant feeding artery originating from the right external pudendal artery, despite coiling one month prior (Fig. 6).
41-year-old man with scrotal AVM. Following Onyx  embolization, flow through the AVM is almost entirely occluded (arrow).
gr7.jpg
PMC4900101_01_gr7.jpg
fig7
This successfully occluded a major portion of the AVM (Fig. 7).